CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

  08 January 2020

CARB-X is awarding Centauri Therapeutics of Sandwich, UK, up to $1.4 million in non-dilutive funding to develop a novel dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens, including drug-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii.

“Centauri’s project is an exciting new approach to treating drug-resistant Gram-negative bacterial infections, and adds rich diversity to CARB-X’s early development portfolio of antibiotics, vaccines, rapid diagnostics and other life-saving products,” said Erin Duffy, Chief of Research and Development of CARB-X, which is based at Boston University School of Law in Boston USA.  “Projects in the Powered by CARB-X portfolio are in the early stages of development, but if successful, each offers tremendous hope and progress in the global fight against drug resistance. CARB-X is led by Boston University and funded by a global partnership.

 

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!